Company: OCEA
Filing Date: 2025-04-08
Form Type: 10-K
Source: 0001641172-25-003155
Chunk: 529

Company: Ocean Biomedical, Inc.
Filing Date: 2025-04-08
Form: 10-K
Item: Item 4
Chunk 529
---
care Acquisition Corp.” to Ocean Biomedical, Inc.” References to the “Company”, “Ocean Biomedical”,
“we”, “us” and “our” refer to the Legacy Ocean prior to the Closing of the Business Combination and
Ocean Biomedical, Inc., formerly known as Aesther Healthcare Corp., on a consolidated basis with Legacy Ocean, for periods after the
Closing of the Business Combination.

Overview

We
are a biopharmaceutical company that seeks to bridge the “bench-to-bedside” gap between medical research discoveries and
patient solutions. We do this by leveraging our strong relationships with research universities and medical centers to license their
inventions and technologies with the goal of developing them into products that address diseases with significant unmet medical needs.
We believe that our differentiated business model positions us to capture inventions created at these institutions that might otherwise
fail to be commercialized to benefit patients. Our team of accomplished scientists, business professionals and entrepreneurs bring together
the interdisciplinary expertise and resources required to develop and commercialize a diverse portfolio of assets. We are organized around
a licensing and subsidiary structure that we believe will enable us to create mutual value both for us and potential licensing partners.
We believe this structure, combined with the professional networks of our leadership team members, allows us to opportunistically build
a continuous pipeline of promising product innovations through our existing and potential future relationships with research institutions.
Our goal is to optimize value creation for each of our product candidates, and we intend to continuously assess the best pathway for
each as it progresses through the preclinical and clinical development process—including through internal advancement, partnerships
with established companies and spin-outs or initial public offerings, (“IPOs”)—in order to benefit patients through
the commercialization of these products. Our current active assets are licensed from Brown University and Rhode Island Hospital. Our
scientific co-founders and members of our Board of Directors (“Board”), Dr. Jack A. Elias and Dr. Jonathan Kurtis, are both
affiliated with Brown University and with Rhode Island Hospital. Our strategy is to accelerate the flow of the academic discoveries and
the required clinical development required for these product candidates and advance them commercially. The number of potential opportunities
at research universities and medical centers is large, but only a small fraction of these opportunities is currently tapped in the market.
The gap remains wide and we believe this presents an attractive opportunity for us to become an industry leader by addressing a need
to accelerate the advancement of therapeutics that can address significant unmet medical needs.